SOURCE: Fresh Start Private Management Inc.

Fresh Start Private Management Inc.

November 18, 2010 18:59 ET

Fresh Start Private Management Inc. Signs Exclusive License Agreement With Trinity RX Solutions for Naltrexone Implant

Naltrexone Recently Approved by Federal Drug Administration as a Treatment for Alcoholism

LOS ANGELES, CA--(Marketwire - November 18, 2010) - Fresh Start Private (OTCBB: CEYY), a leader in the alcohol treatment and rehabilitation industry, today announced that it has signed an exclusive agreement with Trinity Rx Solutions (TRS) of New York, the manufacturer of the Naltrexone Implant Product used in the Fresh Start Private Management Inc (FSPM) treatment program.

Naltrexone is a medication that blocks the effects of drugs known as opioids. Originally used to treat dependence on opioid drugs, it was recently approved by the Federal Drug Administration as treatment for alcoholism.

Under the terms of the agreement only FSPM patients will have access to TRS's ground breaking Naltrexone Implant, which helps patients overcome urges to abuse alcohol by blocking the euphoric effects. FSPM clients are treated with a slow release dose that lasts for a year, giving the Company a higher success rate in the treatment of alcoholism than other methods.

More than 7% of the population ages 18 years and older or 13.8 million Americans have problems with drinking, including 8.1 million people who suffer from alcoholism. And the costs financially are staggering. Alcohol dependence and abuse cost the US over $220 billion a year; greater than the amount of money spent to combat cancer ($196 billion) or obesity ($133 billion).

Under the terms of the agreement, FSPM will issue 7.5% of its issued and outstanding shares equaling 5,672,250 restricted common shares to Trinity RX Solutions, LLC.

About Fresh Start Private

Fresh Start Private is an alcohol addiction, alcohol withdrawal, alcohol abuse treatment and alcohol detox rehabilitation company on the leading edge of addiction treatment. The Company has developed a patented highly effective treatment that delivers target therapeutic levels of Naltrexone that significantly reduce patients' cravings for alcohol. To date, more than 5,000 patients have received the Fresh Start Private Naltrexone implant.

For more information visit

The information in this release includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Although the company believes that its expectations are based on reasonable assumptions, actual results may differ materially. These forward-looking statements involve risks and uncertainties that include, among others, market demand for, and/or available supplies of products and services; unanticipated delays, risks related to competition, management of growth, new products, services and technologies, potential fluctuations in operating results, commercial agreements, acquisitions and strategic transactions, government regulation and taxation. More information about factors that potentially could affect the Company's financial results is included in its filings with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information

  • Contact
    Dr. Jorge Andrade
    714- 514 6100